<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02567448</url>
  </required_header>
  <id_info>
    <org_study_id>UCSD130851</org_study_id>
    <nct_id>NCT02567448</nct_id>
  </id_info>
  <brief_title>Pathophysiology of the Upper Airway in Patients With COPD and Concomitant OSA</brief_title>
  <official_title>Pathophysiology of the Upper Airway in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Concomitant Obstructive Sleep Apnea (OSA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of study is to evaluate the physiologic effects of pulmonary tissue/structural
      changes associated with COPD and upper airway inflammation on upper airway collapsibility.
      Upper airway collapsibility is closely associated with development of obstructive sleep apnea
      (OSA), which is a common disease characterized by repetitive collapse of upper airway during
      sleep, leading to hypoxemia and arousal. OSA has important neurocognitive and cardiovascular
      consequences, especially in patients with COPD.

      Participants in this research study will undergo two overnight sleep studies (PSGs),
      pulmonary function test, and CT scan of the upper airway and chest. The first sleep study
      will evaluate the sleep breathing disorder and the second sleep study will measure the upper
      airway collapsibility, called critical closing pressure (Pcrit). Pcrit is measured by a
      modified continuous positive airway pressure (CPAP) machine which can provide a wide range of
      pressures between 20 and -20 cmH2O in order to modify upper airway pressure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a physiologic study to assess the effects of lower airway and lung tissue changes of
      COPD on upper airway collapsibility. Increased in lung volume and destruction of alveolar
      wall in COPD may have opposite and various effects on the upper airway collapsibility, which
      is an important factor of OSA development.

      Chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) are very
      common disorders associated with considerable morbidity, mortality, and healthcare costs. The
      prevalence of both co-existing conditions is estimated to be ~4% of the general population.
      This COPD-OSA &quot;overlap&quot; syndrome causes more severe hypoxemia than either COPD or OSA alone
      and has important clinical consequences, including death. COPD is usually excluded in OSA
      research and OSA is typically excluded or not assessed in studies of COPD; thus, available
      information about the &quot;overlap&quot; syndrome is limited. Therefore, it is important to identify
      patients with both COPD and OSA and determine the mechanisms of poor outcomes for these
      patients in order to optimize therapy. The pathophysiology of the COPD-OSA syndrome is not
      well understood. The investigators propose to investigate upper airway (UA) anatomic
      characteristics and collapsibility as potential underlying mechanisms that may help to
      explain the negative additive effect of having both conditions. The objectives are to study
      CT measures of airway anatomy and the critical closing pressure of the upper airway (Pcrit),
      a gold standard measure of upper airway collapsibility, in patients with COPD-OSA compared
      with COPD only and normal controls. CT scan of upper airway and chest will allow precise
      measures of upper airway characteristics and COPD associated alveolar and lower airway ch.
      angesMeasures of upper airway collapsibility will provide us information about the mechanical
      nature of the airway and if the patients are more likely to have OSA. Subjects with COPD-OSA
      may exhibit more upper airway inflammation possibly due to their pre-existing COPD disease
      and the reoccurring opening and closing of the upper airway due to the OSA. Therefore the
      investigators would like to assess the degree of inflammation in these patients compared to
      normal controls.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Critical closing pressure (PCrit)</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured during overnight sleep study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharyngeal lavage cell count distribution</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal later airway dimension (mLAT)</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured from upper airway CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal anteroposterior airway dimension (mAP)</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured from upper airway CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal cross sectional airway area (mCSA)</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured from upper airway CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lateral airway dimension on hard palate/uvula/epiglottis level</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured from upper airway CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anteroposterior airway dimension on hard palate/uvula/epiglottis level</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured from upper airway CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cross-sectional airway area on hard palate/uvula/epiglottis level</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured from upper airway CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distance between the lower edge of the mandible and the lower edge of the hyoid (MH)</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured from upper airway CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Upper airway length</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured from upper airway CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Width of hard palate</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured from upper airway CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasophayngeal/retropalatal/retroglossal pharyngeal cavity volume</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured from upper airway CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume within the cervico-mandibular bony frame</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured from upper airway CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of retropalatal/retroglossal soft tissue</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parapharyngeal fat pad volume</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tongue volume</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emphysema score</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured from CT chest scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emphysema distribution</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured from CT chest scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower airway wall thickness on chest CT scan</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured from CT chest scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume in 1 second (FEV1)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total lung capacity (TLC)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of residual volume / total lung capacity (RV/TLC)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diffusing capacity of the lung for carbon monoxide (DLCO)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>COPD Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who were previously diagnosed of moderate to severe COPD as determined by spirometry. All patients will have sleep and pulmonary physiologic measurements.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who are healthy, without major medical or sleep problems, and have normal spirometry. All patients will have sleep and pulmonary physiologic measurements.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sleep and pulmonary physiologic measurements</intervention_name>
    <description>Two overnight sleep studies, CT scan of upper airway and chest, pulmonary function test and pharyngeal lavage</description>
    <arm_group_label>COPD Group</arm_group_label>
    <arm_group_label>Normal Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for COPD Subjects:

          -  Age range 40-70 years.

          -  Demonstrated moderate to severe COPD as determined by spirometry (post-bronchodilator
             spirometry FEV1/FVC &lt; 0.70 for diagnosing CODP and FEV1&lt;80% predicted for staging)

          -  Smoking history of â‰¥ 10 pack-years

        Inclusion Criteria for Control Subjects

          -  Age range 40-70 years

          -  Demonstrated no COPD as determined by normal spirometry (post-bronchodilator
             spirometry FEV1/FVC &gt; 0.70 for diagnosing CODP and FEV1&lt;80% predicted for staging)

          -  No smoking history as defined by less than 100 cigarettes smoked in a lifetime

        Exclusion Criteria for both COPD and Control Subjects:

          -  Metal objects that may interfere with chest CT quantification including presence of a
             cardiac pacemaker, defibrillator, metal prosthetic heart valve, metal projectile or
             metal weapon fragment (bullet, shrapnel, shotgun shot) or metal shoulder prosthesis

          -  Subjects unable to perform spirometry due to:

               -  chest or abdominal surgery in the past three months

               -  a heart attack in the last three months

               -  detached retina or eye surgery in the past three months

               -  hospitalization for any other heart problem in the past month

          -  History of hypersensitivity to Afrin, Lidocaine or albuterol

          -  A psychiatric disorder, other than mild depression; e.g. schizophrenia, bipolar
             disorder, major depression, panic or anxiety disorders.

          -  More than 10 cups of beverages with caffeine (coffee, tea, soda/pop) per day

          -  Pregnancy or suspected pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Soler, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Owens, MD</last_name>
    <phone>619-471-9505</phone>
    <email>rowens@ucsd.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pamela DeYoung</last_name>
    <phone>619-471-0221</phone>
    <email>pdeyoung@ucsd.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Smales, RPSGT</last_name>
      <phone>619-471-9484</phone>
      <email>esmales@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Owens, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2015</study_first_submitted>
  <study_first_submitted_qc>October 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2015</study_first_posted>
  <last_update_submitted>February 16, 2017</last_update_submitted>
  <last_update_submitted_qc>February 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Robert L. Owens</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Obstructive Sleep Apnea</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Overlap syndrome</keyword>
  <keyword>Pcrit</keyword>
  <keyword>Critical closing pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

